Update on the management of hypertension for secondary stroke prevention

European Neurology

Volumn 68, Issue 1, 2012, Pages 1-7

  Castilla Guerra, Luis ^a   Del Carmen Fernnádez Moreno, María ^b,c  

^a HOSPITAL DE LA MERCED   (Spain)

^b HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^c NONE   (Spain)

Author keywords

AHA ASA guidelines; Blood pressure treatment; Hypertension; Risk factors; Stroke; Stroke prevention

Indexed keywords

ANTIHYPERTENSIVE AGENT; EPROSARTAN; INDAPAMIDE; NITRENDIPINE; PERINDOPRIL; PLACEBO; TELMISARTAN;

BLOOD PRESSURE REGULATION; BRAIN PERFUSION; CAROTID ARTERY OBSTRUCTION; CLINICAL TRIAL (TOPIC); HUMAN; HYPERTENSION; MEDICAL SOCIETY; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STROKE;

EID: 84861330548     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000336836     Document Type: Review

References (28)

1. Lawes CM, Bennett DA, Feigin VL, Rodgers A: Blood pressure and stroke: an overview of published reviews. Stroke 2004; 35: 776-785. (Pubitemid 38280858)
2. Castilla-Guerra L, Fernández-Moreno M del C, Alvarez-Suero J: Secondary stroke pre-vention in the elderly: new evidence in hy-pertension and hyperlipidemia. Eur J Intern Med 2009; 20:586-590.
3. Furie KL, Kasner SE, Adams RJ, et al: Guide-lines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2011; 42:227-276.
4. PROGRESS Collaborative Study Subgroup: Randomized trial of perindopril based blood pressure-lowering regimen among 6,108 in-dividuals with previous stroke or transient ischemic attack. Lancet 2001; 358: 1033-1041.
5. PATS Collaborating Group: Post-stroke an-tihypertensive treatment study: a prelimi-nary result. Chin Med J (Engl) 1995; 108: 710-717.
6. Schrader J, Luders S, Kulschewski A, et al: Morbidity and mortality after stroke - epro-sartan compared with nitrendipine for sec-ondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
7. Yusuf S, Diener HC, Sacco RL, et al: Telmi-sartan to prevent recurrent stroke and car-diovascular events. N Engl J Med 2008; 359: 1225-1227.
8. Castilla-Guerra L, Fernández-Moreno M del C, Espino-Montoro A, López-Chozas JM: Ambulatory blood pressure monitoring in stroke survivors: do we really control our pa-tients? Eur J Intern Med 2009; 20:760-763.
9. Sare GM, Gray LJ, Wardlaw J, Chen C, Bath PM, ENOS Trial Investigators: Is lowering blood pressure hazardous in patients with significant ipsilateral carotid stenosis and acute ischaemic stroke? Interim assessment in the 'Efficacy of Nitric Oxide in Stroke' tri-al. Blood Press Monit 2009; 14:20-25.
10. Ruland S, Aiyagari V: Cerebral autoregula-tion and blood pressure lowering. Hyperten-sion 2007; 49: 977-978. (Pubitemid 351664329)
11. Kaplan NM, Rose BD: Treatment of hyper-tension in patients who have had a stroke. www.uptodate.com (accessed September, 2010).
12. Kantola I, Terent A, Kataja M, Breig-Asberg E: Ace-inhibitor therapy with spirapril in-creases nocturnal hypotensive episodes in elderly hypertensive patients. J Hypertens 2001; 15:873-878. (Pubitemid 34056043)
13. Rothwell PM, Howard SC, Spence JD, the Carotid Endarterectomy Trialists' Collabo-ration: Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke 2003; 34: 2583-2590. (Pubitemid 37392745)
14. Novak V, Hu K, Desrochers L, et al: Cerebral flow velocities during daily activities depend on blood pressure in patients with chronic ischemic infarctions. Stroke 2010; 41:61-66.
15. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al: A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Tran-dolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
16. The ONTARGET Investigators: Telmisar-tan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559.
17. Zanchetti A, Grassi G, Mancia G: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reap-praisal. J Hypertens 2009; 27:923-934.
18. Chrysant SG: Effectiveness of lowering blood pressure to prevent stroke versus to prevent coronary events. Am J Cardiol 2010; 106:825-829.
19. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, Schron EB, Lindholm LH: Treat-ment of hypertension in patients 80 years and older: the lower the better? A meta-anal-ysis of randomized controlled trials. J Hy-pertens 2010; 28:1366-1372.
20. Arima H, Chalmers J, Woodward M, et al, the PROGRESS Collaborative Group: Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24:1201-1208. (Pubitemid 43772329)
21. Schrader J, Lüders S, Kulschewski A, et al: The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699-1703. (Pubitemid 36842630)
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R Dagenais G: Effects of an angiotensin-con-verting-enzyme inhibitor, ramipril, on car-diovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
23. Lindholm LH, Ibsen H, Dahlöf B, et al: Car-diovascular morbidity and mortality in pa-tients with diabetes in the Losartan Inter-vention For Endpoint reduction in hyperten-sion study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:1004-1010. (Pubitemid 34286537)
24. Castilla-Guerra L, Fernández-Moreno MC, Jiménez-Hernandez MD: Blockage of the re-nin-angiotensin system in the secondary prevention of stroke: beneficial effects be-yond blood pressure reduction? Stroke 2009; 40:e75.
25. Strauss MH, Hall A: Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings: no. Stroke 2009; 40:3161-3162.
26. Diener HC, Wong P: Development in sec-ondary stroke prevention. Eur Neurol Rev 2008; 48:50-57.
27. Diener HC: Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial pro-grams. J Hypertens Suppl 2009; 27:S31-S36.
28. Lu GC, ChengJW, Zhu KM, et al: A system-atic review of angiotensin receptor blockers in preventing stroke. Stroke 2009; 40:3876-3878.